Bruce Loxley GSK

Bruce provides inspection readiness and compliance guidance to GSK Vaccines and Medicines manufacturing network, focusing on AsiaPac. He is responsible for performing pre- Prior Approval Inspection (PAI) Assessments, and now has a specific remit on (i) preparing sites for first inspection, and on (ii) sharing knowledge on regulatory updates and trends into the organization. Bruce has more than 30 years in the Pharma and Vaccines businesses, including a variety of roles in Validation and Compliance in both Drug Substance and Drug Product Manufacturing in UK, France and Singapore. Bruce has been a PDA Singapore Chapter member since 2014 and was Chapter President from 2020-2022. Since July 2022 he has been a member of PDA’s Science Advisory Board (SAB). As such, he is a committee member in the drafting of the upcoming Points to Consider on RABS systems to be published early 2025.